Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Papaverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.71 |
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.97 |
| ▸ | PDE3B | Q13370 | 9/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | USP2 | O75604 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | PDE4A | P27815 | 2/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.97 |
| ▸ | PDE2A | O00408 | 1/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Papaverine SCHEMBL28169527 | 1.00 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29360983 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL34702 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29387160 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL9551009 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL8691148 | 0.97 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29696479 | 0.97 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29356374 | 0.97 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL5500363 | 0.97 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL121268 | 0.97 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020234454-A1 | COMBINATION TREATMENT OF CANCER TARGETING ENERGY METABOLISM AND INTRACELLULAR PH | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-11-26 | — | — | WO | claimed |
| EP-4676453-A1 | METHODS FOR THE TREATMENT OF FOOD ALLERGY | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-01-14 | — | — | EP | disclosed |
| US-20250064830-A1 | TRANSDERMAL TREATMENT FOR ERECTILE DYSFUNCTION | MADERA PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024184479-A1 | METHODS FOR THE TREATMENT OF FOOD ALLERGY | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-09-12 | — | — | WO | disclosed |
| US-12053479-B2 | Transdermal treatment for erectile dysfunction | Madera Pharm aceuticals, Inc. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4232002-A1 | TRANSDERMAL TREATMENT FOR ERECTILE DYSFUNCTION | Standard International Group Holdings, LP (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | disclosed |
| CN-115260095-A | Novel crystal form of papaverine hydrochloride and preparation method thereof | 安徽恒星制药有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11466020-B2 | Compounds and compositions for inhibition and elimination of Zika infection and uses for same | CORNELL UNIVERSITY (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022087496-A1 | TRANSDERMAL TREATMENT FOR ERECTILE DYSFUNCTION | Standard International Group Holdings, LP (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| EP-0927048-B1 | MARKER COMPOSITIONS | AMERSHAM HEALTH AS (NO) | 2003-11-12 | — | — | EP | disclosed |
| US-20020102214-A1 | Paramagnetic material-containing magnetic resonance external marker or calibration composition | NYCOMED IMAGING AS. | 2002-08-01 | — | — | US | disclosed |
| EP-0927048-A2 | MARKER COMPOSITIONS | NYCOMED IMAGING AS (NO) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998010797-A2 | MARKER COMPOSITIONS | NYCOMED IMAGING AS (NO) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | ACHE 712/4885CHRM1 1980/4885PDE10A 2670/4885 |
| US-12053479-B2 | Transdermal treatment for erectile dysfunction | PTGER1, PTGIS, PDE3A | ACHE 154/4885CHRM1 101/4885PDE10A 30/4885 |
| US-20020102214-A1 | Paramagnetic material-containing magnetic resonance external marker or calibration composition | S100P, SET, GUCY1A1 | ACHE 3633/4885CHRM1 1750/4885PDE10A 3461/4885 |
| US-20250064830-A1 | TRANSDERMAL TREATMENT FOR ERECTILE DYSFUNCTION | PTGER1, PTGIS, PDE3A | ACHE 154/4885CHRM1 101/4885PDE10A 30/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885CHRM1 24/4885PDE10A 434/4885 |
| US-11466020-B2 | Compounds and compositions for inhibition and elimination of Zika infection and uses for same | ZC3HAV1, HAVCR2, TTPA | ACHE 106/4885CHRM1 4451/4885PDE10A 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.